Sharemaestro company-news research for Immuron Ltd ADR (IMRN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest IMRN news and sentiment
Immuron Ltd ADR
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score55Neutral is 50
Early balanced news score
30/100 evidence confidence
100% direct company focus
15 current stories across 5 publishers
Current company news
Early balanced news score
15 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone66/100
→
Published 30-day score55/100
Latest source headline
Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS
MT Newswires · 04 Sep 2026 17:51
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
15 current stories are mapped specifically to IMRN.
The score uses 5 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.443.
Confidence is 30/100, below the threshold for a firm score.
55/100
News scoreEarly balanced news score
30/100
Confidencethin evidence
100%/100
Company news15 company stories
87/100
Story agreement13/100 difference
News history
Daily score and story count over 30 days
07 Aug22 Aug05 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence9
0.443 after freshness weightingSource breadth100
5 independent publishersCompany relevance100
share tied directly to this companyFreshness42
recency-weighted evidenceAgreement87
how closely stories agreePublisher mix79
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
04 Sep 202654USD 1.8+56.5%
28 Aug 202658USD 1.15+2.7%
21 Aug 202652USD 1.12+1.8%
14 Aug 202651USD 1.1+6.7%
07 Aug 202653USD 1.031-5.4%
31 Jul 202651USD 1.09-1.8%
24 Jul 202653USD 1.11-8.3%
17 Jul 202658USD 1.21-1.6%
Provisional evidence
News subjects
What is shaping the score
Earnings679 stories · 60%
Market update533 stories · 20%
Balance sheet452 stories · 13%
Deals and strategy501 stories · 7%
Source mix
Where the evidence comes from
Stock Titan474 stories · 27%
Kalkine792 stories · 13%
Kalkine Media642 stories · 13%
GlobeNewswire502 stories · 13%
Quiver Quantitative711 stories · 7%
Stocktwits571 stories · 7%
MT Newswires501 stories · 7%
Recurring subjects
Subjects appearing most often
Earnings7Life Sciences6Finance3Ratings1Earnings News1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
19 Jun50 neutral05 Sep 13:16
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 05 Sep 13:16 | 54 | +0 | 27/100 (-1) | 15 (0) | Provisional |
| 04 Sep 23:59 | 54 | -4 | 28/100 (-12) | 15 (+3) | Provisional |
| 28 Aug 23:59 | 58 | +6 | 40/100 (+10) | 12 (-6) | Measured |
| 19 Aug 23:59 | 52 | +1 | 30/100 (+13) | 18 (-2) | Provisional |
| 18 Aug 23:59 | 51 | -1 | 17/100 (-3) | 20 (-8) | Provisional |
| 13 Aug 23:59 | 52 | -2 | 20/100 (-9) | 28 (+1) | Provisional |
| 05 Aug 23:59 | 54 | +2 | 29/100 (-4) | 27 (0) | Provisional |
| 28 Jul 23:59 | 52 | +0 | 33/100 (-2) | 27 (0) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
MT NewswiresDirect company coverageScored from headline
Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS
- Published
- 04 Sep 2026 17:51
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.2d old
- Duplicates
- 1 consolidated
#257Tone
StocktwitsDirect company coverageScored from headline
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
- Published
- 04 Sep 2026 14:50
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 47/100
- 30-day weight
- 14.2% of the score · 0.3d old
- Duplicates
- 1 consolidated
#3—Not directional
InvestorsHubDirect company coverageScored from headline
Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement
- Published
- 04 Sep 2026 13:53
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.4d old
- Duplicates
- 1 consolidated
#4—Not directional
GlobeNewswireDirect company coverageScored from headline
Immuron to launch PROIBS® in the United States
- Published
- 04 Sep 2026 10:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.5d old
- Duplicates
- 1 consolidated
#542Tone
Stock TitanDirect company coverageScored from headline
Immuron (NASDAQ: IMRN) ends FY26 with A$9.0m cash but stays in loss
- Published
- 28 Aug 2026 12:45
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 44/100
- 30-day weight
- 14.9% of the score · 7.4d old
- Duplicates
- 1 consolidated
#6—Not directional
seekingalpha.comDirect company coverageStored article
Immuron reports FY results
* Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. * Net loss of A$3.8M, improvement of A$1.4M. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking Alpha’s Quant Rating on Immuron [https://seekingalpha.com/symbol/IMRN/ratings/quant-ratings] * Historical earnings data for
EarningsEarnings NewsRatings
- Published
- 28 Aug 2026 10:12
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.5d old
- Duplicates
- 1 consolidated
#771Tone
Quiver QuantitativeDirect company coverageScored from headline
Immuron Limited Reports Record FY26 Sales, Improved Profit and Key Pipeline Milestones
- Published
- 28 Aug 2026 10:11
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 55/100
- 30-day weight
- 15.7% of the score · 7.5d old
- Duplicates
- 1 consolidated
#8—Not directional
Stock TitanDirect company coverageScored from headline
Immuron's cash rose A$6.2M to A$9M; its C. diff drug is ready for Phase 2
- Published
- 28 Aug 2026 10:00
- News subject
- Balance sheet
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.5d old
- Duplicates
- 1 consolidated
#9—Not directional
GlobeNewswireDirect company coverageScored from headline
Immuron Reports FY26 Preliminary Results
- Published
- 28 Aug 2026 10:00
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.5d old
- Duplicates
- 1 consolidated
#1081Tone
KalkineDirect company coverageStored article
Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E
Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan® sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.
EarningsFinanceLife Sciences
- Published
- 28 Aug 2026 09:15
- News subject
- Earnings
- Why this score
- Loss narrowed, Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 67/100
- 30-day weight
- 28.8% of the score · 7.6d old
- Duplicates
- 1 consolidated
#1165Tone
Kalkine MediaDirect company coverageStored article
Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss
Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.
EarningsLife Sciences
- Published
- 28 Aug 2026 09:15
- News subject
- Earnings
- Why this score
- Operating growth, Improving financial comparison, Fda Approval
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 21.8% of the score · 7.6d old
- Duplicates
- 1 consolidated
#1259Tone
Stock TitanDirect company coverageStored article
Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development
Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and ProIBS, while seeking partners to fund the development and commercialization of its clinical assets IMM-124E and IMM-529. This shift aims to reduce R&D expenditure and cash burn, leveraging upfront fees, milestones, and royalties from licensing agreements.
EarningsLife Sciences
- Published
- 19 Aug 2026 10:11
- News subject
- Earnings
- Why this score
- Cash generation improved, Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 4.6% of the score · 16.5d old
- Duplicates
- 1 consolidated
#13—Not directional
KalkineDirect company coverageStored article
Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference
Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan® for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS® for IBS symptoms.
EarningsFinanceLife Sciences
- Published
- 18 Aug 2026 23:40
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.0d old
- Duplicates
- 1 consolidated
#14—Not directional
Stock TitanDirect company coverageStored article
Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference
Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelan® for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, and the distribution of ProIBS® for IBS symptoms. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.
EarningsLife Sciences
- Published
- 13 Aug 2026 09:42
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.5d old
- Duplicates
- 1 consolidated
#15—Not directional
Kalkine MediaDirect company coverageStored article
Immuron CEO Steven Lydeamore to Deliver Virtual Presentation at Emerging Growth Conference on August 19, 2026
Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Eastern Time. The company, an Australian biopharmaceutical firm, specializes in orally delivered targeted polyclonal antibodies for infectious diseases, with its flagship product Travelan AE targeting travelers' diarrhea. Immuron is also developing IMM-529 for Clostridioides difficile infection.
EarningsFinanceLife Sciences
- Published
- 13 Aug 2026 09:15
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.6d old
- Duplicates
- 2 consolidated
Earlier company news
IMRN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 32 older IMRN headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to IMRN, but the headline and available text are not mainly about Immuron Ltd ADR. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of IMRN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.